Keywords: |
adult; middle aged; treatment failure; mutation; disease course; case report; letter; polymerase chain reaction; allele; computer assisted tomography; amino acid substitution; serine; relapse; recurrence; drug resistance, neoplasm; enzyme activity; pyrimidines; phosphorylation; drug dose escalation; enzyme phosphorylation; blood sampling; pyrazoles; nucleotide sequence; drug response; protein-tyrosine kinases; point mutation; chronic lymphatic leukemia; lymphadenopathy; drug protein binding; leukemia, lymphocytic, chronic, b-cell; genomic dna; lymphocyte count; cysteine; electrophoresis; complementary dna; thymidine; rna sequence; enzyme active site; sequence analysis, dna; adenine; receptors, antigen, b-cell; covalent bond; drug concentration; thiol derivative; bruton tyrosine kinase; ibrutinib; humans; human; female; priority journal; maximal inhibitory concentration
|